EXPLORE THE SCIENCE
TL;DR: A 2026 narrative review in Clinical Drug Investigation argued that desvenlafaxine, a serotonin-noradrenaline reuptake inhibitor (SNRI), may be a first-line major depressive disorder option for selected patients, especially when fatigue, cognitive compla…
Read article
Moderate alcohol intake in men treated with SNRI antidepressants significantly increases the risk of depression relapse, according to a new study. Highlights: Risk Increase with SNRIs: Men with moderate alcohol consumption and elevated liver enzymes are signif…
Read article
Antidepressant withdrawal symptoms occur in about one-third of patients stopping antidepressants, with severe symptoms in about 3% of cases – according to a new Lancet Psychiatry review. Highlights: Incidence of Symptoms: Approximately 31% of patients experien…
Read article
Depression is highly prevalent in older adults and those with cardiovascular disease. Selective serotonin reuptake inhibitors (SSRIs) are generally safe first-line treatments, but many wonder if they’re safe for those with cardiovascular disease. Key Facts: Th…
Read article
Current antidepressants can take weeks to improve symptoms of depression. New research explores reasons for this delay and provides clues to develop more rapid-acting drugs. Key Facts: Most antidepressants increase brain serotonin and norepinephrine, but their…
Read article
Antidepressants could potentially be repurposed as anticancer agents based on emerging evidence showing they can modulate autophagy—a process cancer cells rely on for growth and survival. Key Facts: Many antidepressants like SSRIs and TCAs have demonstrated an…
Read article